Research and Development of New Strategies for the Early Detection and Prevention of Gastric Cancer in the Spanish Population: EpiGASTRIC/EDGAR Project.
Sponsor study identifier
observational
1,200
1 country
15
Study Start
September 9, 2021
Actual (reported)Primary Completion
September 30, 2025
Actual (reported)Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is a multicenter, prospective cohort study, which are planned to enroll at least 600 patients who diagnosed the primary gastric cancer (GC); around 50 patients with premalignant gastric lesions (PGLs) and early gastric neoplasias (EGC) treated by endoscopy resection; and no less than 600 healthy normal cohort participants, for more than 18 months in the Spanish population. All participants who enrolled in this registry will be questioned by the life habits survey; and clinical data and biological samples of these participants were analyzed in order to look for new diagnostic tools. The aim of this study is to evaluate clinical, endoscopic and molecular approaches to identify individuals with high-risk of GC. Thus, it would be allow the adoption of preventive measures to reduce mortality through early detection and/or the reduction of its incidence.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 9, 2021
Actual (reported)September 6, 2022
Actual (reported)September 22, 2022
Actual (reported)September 30, 2025
Actual (reported)December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
New strategies for gastric cancer (GC) early diagnosis
Prediction of risk factors and identification of new strategies for an early diagnosis of GC.
Up to 10 years
Prevalence of premalignant gastric lesions (PGLs)
Up to 5 years
Endoscopic characterization of PGLs
Up to 5 years
Patients with GC.
Symptomatic patients subjected to a diagnostic gastroscopy to study the prevalence of premalignant gastric lesions.
Patients with premalignant gastric lesions and early gastric neoplasias treated by endoscopy resection.
Demographics, life habits and risk factors studies
This cohort study is designed to enroll the Spanish population patients who are diagnosed gastric cancer; symptomatic patients subjected to a diagnostic gastroscopy who have or not premalignant gastric lesions and early gastric neoplasias susceptible to be treated by endoscopy resection; and healthy control participants by multicenter-prospective registry. Nevertheless, the study will be open to international participation.
Hospital Comarcal de Inca
Palma de Mallorca, Balearic Islands, Spain
Hospital de Llevant
Porto Cristo, Balearic Islands, Spain
Hospital Clínic de Barcelona
Barcelona, Barcelona, Spain
Herrera-Pariente C, Montori S, Llach J, Bofill A, Albeniz E, Moreira L. Biomarkers for Gastric Cancer Screening and Early Diagnosis. Biomedicines. 2021 Oct 12;9(10):1448. doi: 10.3390/biomedicines9101448.
Herrera-Pariente C, Capo-Garcia R, Diaz-Gay M, Carballal S, Munoz J, Llach J, Sanchez A, Bonjoch L, Arnau-Collell C, Soares de Lima Y, Golubicki M, Jung G, Lozano JJ, Castells A, Balaguer F, Bujanda L, Castellvi-Bel S, Moreira L. Identification of New Genes Involved in Germline Predisposition to Early-Onset Gastric Cancer. Int J Mol Sci. 2021 Jan 28;22(3):1310. doi: 10.3390/ijms22031310.
Nucleic acids and proteins will be obtained from the biological samples.
First Submitted
September 6, 2022
First Posted
September 22, 2022
Study Start
September 9, 2021
Actual (reported)Primary Completion
September 30, 2025
Actual (reported)A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients
Identification of GC hereditary predisposition by a customize multigene panel
Up to 5 years
Identification of GC risk factors from clinical data and a lifestyle survey
Up to 5 years
Discover and validation of new biomarkers for early diagnosis of GC
Up to 5 years
Patients from "EDGAR 1" without gastric pathology or familial history of this neoplasia.
Identification and characterization of premalignant gastric lesions through high definition endoscopic study. Concordance between endoscopic and histological classifications
Multiomic studies
Genomic studies for the identification of individuals with hereditary GC predisposition
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Hospital General de Granollers
Granollers, Barcelona, Spain
Consorci Sanitari de Terrassa
Terrassa, Barcelona, Spain
Hospital Santos Reyes
Aranda de Duero, Burgos, Spain
Hospital Universitario de Burgos
Burgos, Burgos, Spain
Hospital de Mérida
Mérida, Extremadura, Spain
Hospital Universitario de Ourense
Ourense, Galicia, Spain
Hospital Josep Trueta
Girona, Gerona, Spain
Hospital Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Universitario de Navarra
Pamplona, Navarre, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Zaragoza, Spain
Hospital Universitario Miguel Servet
Zaragoza, Zaragoza, Spain
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 21, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: